Merck KGaA to Buy Millipore for $7.2 Billion
German pharmaceutical and chemicals company Merck KGaA will buy US biotech equipment-maker Millipore for $7.2 billion.
German pharmaceutical and chemicals company Merck KGaA will buy US biotech equipment-maker Millipore for $7.2 billion. The merger marks Merck’s foray into bioresearch and equipment for biopharmaceutical manufacturing.
Merck plans to retain Millipore’s senior management and also intends to maintain Millipore's headquarters in Billerica, MA, and combine it with Merck’s US chemicals headquarters.
After the acquisition, Merck will get about 35% of its revenue from chemicals, up from the current figure of 25%. The company expects that the acquisition will also generate an annual cost savings of about $100 million within three years of the deal, which it expects to close in the second half of 2010.
The Solution Lies with SOLBIOTE™: Achieving Sustainability, a Growing Focus in Biopharma
October 28th 2024The nexus between biopharmaceuticals and sustainability is seemingly far apart, however, it is increasingly recognized as an inevitable challenge. It is encouraged to take a sustainable approach to reducing the environmental impact of the production and supply of medicines while improving people's health; delivering the well-being of people and the planet. Yosuke Shimojo (Technical Value Support Section Manager, Nagase Viita) will unveil how SOLBIOTE™, a portfolio of injectable-grade saccharide excipients, would be a key for the biopharmaceutical development and achieving sustainability for a better future of the industry.
